Covovax authorisation is a vital step in India, says Novavax CEO
Zee News
The Drugs Controller General of India (DCGI) has issued Emergency Use Authorization (EUA) for Covovax to prevent COVID-19 for adults 18 years old and above.
Pune: Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Serum Institute of India (SII), the world`s largest vaccine manufacturer by volume, on Tuesday, announced that the Drugs Controller General of India (DCGI) has granted emergency use authorisation (EUA) for Novavax`s recombinant nanoparticle protein-based COVID-19 vaccine with Matrix-M adjuvant.
The vaccine will be manufactured and marketed in India by SII under the brand name Covovax.
"No one is safe until everyone is safe, and today`s authorisation marks a vital step for India, where additional vaccine options and millions of doses are needed in the country`s ongoing efforts to control the pandemic," said Stanley C Erck, President and Chief Executive Officer, Novavax.
